Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Levetiracetam (Primary)
- Indications Alzheimer's disease; Cognition disorders; Epilepsy
- Focus Therapeutic Use
- Acronyms LEV in AD
- 31 Aug 2018 Biomarkers information updated
- 18 Jul 2018 Status changed from active, no longer recruiting to recruiting.
- 29 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.